Drug Trial Radar · NCT06223568
Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Jun 10, 2024
Primary completion
Jan 10, 2028
Study completion Jan 10, 2028
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Jan 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 120 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Background: Throat cancer is a common tumor that can occur in people infected with the human papilloma virus (HPV). Most people with this cancer survive more than 5 years with standard chemotherapy drugs plus radiation. But radiation can cause serious adverse effects. Researchers believe that adding a vaccine (PRGN-2009) to this drug therapy may improve survival without the need for radiation. Objective: To test a study vaccine combined with standard chemotherapy in patients with HPV-associated throat cancers. Eligibility: People aged 18 years and older with newly diagnosed throat cancer associated with HPV. Design: Participants will be screened. They will have a physical exam and blood tests. They will have imaging scans and tests of their heart function and hearing. They will provide a sample of tissue from their tumor. A recent sample may be used; if none is available, a new sample will be taken. All participants will get two common drugs for treating cancer. These drugs are given through a tube attached to a needle inserted into a vein in the arm. Participants will receive these drugs on the first day of three 3-week cycles. Half of the participants will also get the vaccine. PRGN-2009 is injected under the skin in the arm. They will get these shots 4 times: 7 days before the start of the first cycle and on the 11th day of each cycle. Participants will have standard surgery to remove their tumors 3 to 6 weeks after completing the study treatment. They will have follow-up visits 3, 6, 12, and 24 months after their surgery. Participants will then be contacted by phone once every year for 3 years. ...
Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Oropharynx
- Human Papillomavirus Viruses
- Drug Therapy
- Cancer Vaccine
Interventions
DocetaxelDrug
Docetaxel 75 mg/m\^2 will be administered over 60 (+/-10) minutes.
CisplatinDrug
Cisplatin 75 mg/m\^2 will be administered over 120 (+/-10) minutes.
PRGN-2009Drug
PRGN-2009 will be administered in Arm 2 participants only as an SQ injection in the arm at a dose of 1 mL nominally containing 5x10\^11 viral particles (VP) on Day -7 (+/-3 days) of Cycle 1, Day 11 (+/-3 days) of Cycles 1, 2, and 3.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine the rate of pCR with NAC (DC) alone or in combination with PRGN-2009 (DCP) in participants with newly diagnosed HPV-associated OPSCCTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Institutes of Health Clinical Center
Bethesda, Maryland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.